Relapsed acute lymphoblastic leukemia, or relapsed ALL, refers to the return of acute lymphoblastic leukemia (ALL) in patients who have already undergone treatment for the disease. Between 15 and 20 percent of children who are treated for ALL and achieve an initial complete remission will have the disease return.
Children and adolescents with relapsed acute lymphoblastic leukemia (ALL) are treated at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center through the Leukemia Treatment Program, one of the top pediatric leukemia treatment programs in the world. Our Leukemia Treatment Program has played a leading role in refining treatment for childhood leukemia, resulting in today’s cure rates of more than 90 percent for ALL, and we continue to lead clinical trials designed to increase cure rates, decrease treatment-related side effects, and improve care for long-term survivors.
We are also a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH for relapsed B-cell ALL for patients who are up to 25 years old.
In relapsed ALL—as with newly diagnosed ALL—lymphocyte stem cells (a type of blood stem cell) become immature white blood cells called lymphoblasts or “blasts.” These blasts do not become healthy white blood cells. Instead, they build up in the bone marrow, so there is less room for healthy white blood cells, red blood cells, and platelets. In addition, these abnormal cells are unable to fight off infection.
The symptoms of relapsed ALL are the same as those for newly diagnosed ALL, including:
To make a diagnosis of pediatric relapsed ALL, a doctor may order a variety of different tests including:
After all tests are completed, doctors will be able to outline the best treatment options.
Treatment of relapsed ALL is typically more intensive than for newly diagnosed ALL. At the time of first relapse, children and adolescents receive reinduction therapy—a treatment course intended to achieve another complete remission. Reinduction therapy typically consists of chemotherapy given by vein (intravenous), by mouth (oral) and into the spinal fluid (intrathecal), and is often similar to treatment that was given when the ALL was first diagnosed.
After achieving a second complete remission, treatment options include 1) chemotherapy with or without radiation and 2) stem cell (bone marrow) transplantation. The treatment strategy recommended for your child will depend on several factors, including:
Patients who relapse in their marrow during or just after completing initial treatment may benefit from a stem cell transplant. Patients who relapse six months or more after initial treatment can often be re-treated with more intensive chemotherapy without a transplant.
Relapses most often occur in the bone marrow. Less commonly, ALL will relapse in the central nervous system (CNS; the brain and spinal fluid) or, in boys, in the testicles, without any bone marrow involvement. As with bone marrow relapses, such cases are treated with aggressive chemotherapy—including, in CNS relapses, intrathecal chemotherapy (treatment delivered to the spinal canal)—but with the addition of radiation therapy targeted to the site of relapse.
Sometimes relapsed ALL does not respond to standard chemotherapy agents. For patients whose leukemia persists (does not go into remission) despite standard treatment approaches, or relapses again (second or greater relapse), the Hematologic Malignancy Center offers clinical trials of many new agents and treatment approaches.
These treatment approaches include:
See our list of open pediatric leukemia clinical trials, which includes trials for relapsed ALL.
Should you have questions or need advice on whether a particular trial would be appropriate for your child, email our clinical trials team at email@example.com. We can help you navigate your options.
The prognosis for children with relapsed ALL depends on a
number of factors, including:
Phone: 617-632-5508Online form: Request an appointment
CAR (chimeric antigen receptor) T-cell therapy is a promising new treatment for some of the most challenging cases we face in pediatric acute lymphoblastic leukemia (ALL).